Immunogenicity remains a primary variable in the clinical translation of AAV-based next-generation therapies. Both pre-existing humoral immunity and induced T-cell responses to the viral capsid can neutralize efficacy and present significant hurdles for IND submission. A proactive strategy, grounded in the rational design of the AAV capsid and the selection of tissue-specific promoters, is fundamental to minimizing clinical risk. This approach directly influences the vector’s tropism, expression profile, and ultimate immunogenic potential, shaping the entire preclinical development pathway.

Rational AAV Capsid and Promoter Design to Mitigate Immunogenicity

Proven Intelligence in Vector Engineering.

Frequently Asked Questions

Strategic Capsid Engineering

The selection of an AAV capsid serotype is a foundational decision. While clinically validated capsids like AAV8 and AAV9 offer predictable tropism profiles, they may also encounter pre-existing neutralizing antibodies in a significant portion of the patient population. An alternative strategy involves engineering novel capsids through directed evolution or rational design to achieve specific goals:

• Immune Evasion: Modifying surface-exposed epitopes to reduce recognition by neutralizing antibodies and T-cells.

• Enhanced Tropism: Refining the capsid to increase transduction efficiency in specific target tissues, allowing for lower, less immunogenic doses.

• Detargeting: Altering the capsid to avoid uptake by antigen-presenting cells, which are key initiators of the anti-vector immune response.

Understanding the nuances of T-cell responses to the AAV capsid is a central component of this process (PMID: 28323492). A well-considered capsid strategy anticipates these interactions to de-risk the program.

Precision Promoter Selection

Controlling transgene expression is as important as controlling vector delivery. The choice of promoter dictates where and at what level the therapeutic protein is produced. A tissue-specific promoter is a powerful tool for minimizing immunogenicity by preventing expression in non-target cells. This targeted approach ensures the therapeutic action is localized, reducing the likelihood of a systemic immune response against the novel protein product. This entire vector design and optimization process is detailed in our webinar on initiating successful AAV programs

.

These foundational design choices have a direct and significant impact on the translational pathway. A vector that is purposefully engineered for low immunogenicity provides a clearer, more interpretable dataset during preclinical evaluation. This foresight was reflected in a recent collaboration: “We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies… The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is our scientific extension in our AAV-vector based gene therapy candidate development.”

This approach, which integrates vectorology with preclinical strategy, has been validated in numerous programs. For instance, studies in nonhuman primate models have shown that a well-designed AAV platform can produce potent and sustained immunogenicity for vaccine applications, confirming the platform’s viability for robust clinical translation (PMID: 33442684). This track record is reflected in the 100% successful IND rate achieved by our core scientific leadership since 2019, a history that predates the formal launch of Franklin Biolabs in 2024.

Return to the main services page to see how our vector production capabilities integrate with our full suite of offerings. Learn more at Vector | CMC | Analytics Services.